FDA VOLUNTARILY WITHDRAWS ALLERGAN TEXTURED BREAST IMPLANT
Important information which may impact you.
Maffi Clinics is committed to education and patient safety, recognizing that providing the most up-to-date information allows our patients to make well-informed decisions. Recent action by the FDA has brought forth discussion regarding breast implants, specifically textured implants and breast implant lymphoma.
WHAT YOU SHOULD KNOW.
Breast implant associated anaplastic large cell lymphoma or BIA-ALCL is an uncommon but treatable type of lymphoma. It is not breast cancer. BIA-ALCL has been associated with textured implants, both silicone and saline. It has not been linked to smooth breast implants.
Symptoms of BIA-ALCL appear 8 to 9 years after the initial breast surgery. The majority of patients experience swelling in one or both breasts. A collection of fluid (seroma) occurs around the implant.
Treatment for BIA-ALCL involves removal of the breast implants along with the capsule or scar tissue that surrounds the implant. The majority of patients are cured following this surgery.
WHAT ACTION TO TAKE.
Allergan and Mentor are pharmaceutical companies that manufacture breast implants. In July of 2019, the FDA asked Allergan to voluntarily withdraw all Allergan Biocell implants, a type of textured implant. The Biocell implant has been associated with the majority of BIA-ALCL cases.
For the majority of breast cases, Dr. Maffi uses Allergan’s smooth, round implants, not textured. Breast implant information including the type of implant is documented on an Implant ID Card, given to each patient following breast surgery. If you are unable to locate your Implant ID card, contact our office and we can assist you.
If you have noticed changes in your breast shape or size, please contact our office to schedule an appointment with Dr. Maffi. If you are a former patient of Dr. Friedland or Dr. Johnson and have questions regarding breast implants, contact our office at 480.505.6430.